Drug development takes a great deal of time, money and effort. While future profits play a big factor in which diseases gets prioritized, advocacy and research incentives can also tilt the scale.
L’expertise universitaire, l’exigence journalistique
Articles sur Drugmakers
Ensemble des articles
The shortages, which have been going on for years, have typically affected only low-cost generics rather than profitable brand-name drugs.
Moderna claims its scientists alone invented the mRNA sequence used to produce its COVID-19 vaccine. The US government, which helped fund the drug, disagrees.
New payment models may mean more of the people who need these treatments can get them.
Each dose of Pfizer has a long and complex path involving mixing, storage at temperatures colder than the South Pole and specific protocols that must be followed before it becomes a jab.
Health Canada devotes far more resources to getting new drugs onto the market compared to making sure that drugs already being sold are safe.
A tragic error showed how complicated it can be to distribute vaccines on a mass scale.
Our best shot at ending the pandemic is by achieving herd immunity through widespread use of a vaccine. But that won’t happen unless people believe it’s safe.
Les contributeurs les plus fréquents
-
Professor of Law and Public Health, The Ohio State University
-
Professor of Law, Villanova School of Law
-
Joel Lexchin est un·e adhérent·e de The Conversation
Professor Emeritus of Health Policy and Management, York University, Canada
-
Professor of Technology and Operations, University of Michigan
-
Senior Lecturer, Film and Media Studies, University of Pittsburgh
-
Dean Emeritus and Distinguished Service Professor Emeritus of Pharmacy, University of Pittsburgh
-
Postdoctoral Fellow in Precision Medicine and Emerging Biotechnologies, Arizona State University
-
Director of Health Policy, USC Schaeffer Center, and Associate Professor, University of Southern California
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
